Trans ε viniferin decreases amyloid deposits and inflammation in a mouse transgenic Alzheimer model

As Alzheimer’s disease (AD) induces several cellular and molecular damages, it could be interesting to use multi-target molecules for therapeutics. We previously published that trans ε-viniferin induced the disaggregation of Aβ(42) peptide and inhibited the inflammatory response in primary cellular...

Descripción completa

Detalles Bibliográficos
Autores principales: Caillaud, Martial, Guillard, Jérôme, Richard, Damien, Milin, Serge, Chassaing, Damien, Paccalin, Marc, Page, Guylène, Rioux Bilan, Agnès
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382128/
https://www.ncbi.nlm.nih.gov/pubmed/30785960
http://dx.doi.org/10.1371/journal.pone.0212663
Descripción
Sumario:As Alzheimer’s disease (AD) induces several cellular and molecular damages, it could be interesting to use multi-target molecules for therapeutics. We previously published that trans ε-viniferin induced the disaggregation of Aβ(42) peptide and inhibited the inflammatory response in primary cellular model of AD. Here, effects of this stilbenoid were evaluated in transgenic APPswePS1dE9 mice. We report that trans ε-viniferin could go through the blood brain barrier, reduces size and density of amyloid deposits and decreases reactivity of astrocytes and microglia, after a weekly intraperitoneal injection at 10 mg/kg from 3 to 6 months of age.

Ejemplares similares